Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd
NCT07446452Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Jan 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07446452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446452.